Trial Profile
A 4 Month Extension to a 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long-term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hypertension.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2011
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Adverse reactions
- 24 Feb 2011 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
- 24 Feb 2011 Additional locations added as reported by ClinicalTrials.gov.
- 14 Jan 2008 Status changed from in progress to completed.